Additional clinical trials are utilizing IGFBP2 as a potential immunotherapy target (NCT00821964) as well as a marker for cancer risk (NCT02450097), for colorectal cancer survival (NCT00503685) and for monitoring breast cancer treatment response (NCT01293032). The gene discussed is IGFBP2; the disease is cancer.